表紙
市場調查報告書

COVID-19大流行對臨床試驗的影響

Coronavirus Disease 2019 (COVID-19) Pandemic Impact on Clinical Trials

出版商 GlobalData 商品編碼 953738
出版日期 內容資訊 英文 52 Pages
訂單完成後即時交付
價格
COVID-19大流行對臨床試驗的影響 Coronavirus Disease 2019 (COVID-19) Pandemic Impact on Clinical Trials
出版日期: 2020年08月01日內容資訊: 英文 52 Pages
簡介

本報告提供COVID-19帶給臨床試驗怎樣的影響,轉移到分散式臨床試驗的可能性相關驗證,以製藥/生物科技,政府/學術機構,CRO,CMO,其他受託服務供應商為對象的調查結果為基礎之系統性資訊。

目錄

第1章 研究設計

第2章 商務、臨床試驗的主要顧慮事項

  • 商務主要的顧慮事項
  • 臨床試驗的主要顧慮事項
  • 臨床試驗的阻礙應對

第3章 轉移到分散式臨床實驗

  • 大流行前的分散式臨床實驗的利用
  • 大流行後的分散式臨床實驗的利用
  • 對分散式臨床試驗的利用的未來趨勢
  • 成本比較

第4章 分散式臨床實驗所面臨的課題

  • 最大的課題
  • 最大的變化

第5章 摘要

第6章 附錄

目錄
Product Code: GDHCHT167

This PowerPoint based report gives an important expert analysis on how COVID-19 is impacting clinical trials and the potential move toward decentralized clinical trials. Findings are based on a survey conducted with 150 respondents from around the world that belonged to Pharma/Biotech, Government/Academic Institutions, CROs, CMOs, or other contract service providers.

The report includes -

  • Background, Objectives and Designs.
  • Primary Concerns, which include business concerns, clinical trial concerns for decentralized clinical trials and addressing trial disruption.
  • Movement Toward Decentralized Trials, including pre and post pandemic decentralized clinical trials use, future movement toward using decentralized clinical trials and cost comparison.
  • Challenges Facing Decentralized Trials, which explores the biggest challenges and changes that are anticipated for decentralized clinical trials.

Scope

  • A total of 150 GlobalData Pharma clients and prospects from the around the world participated in the seven-minute survey, which was fielded from June 4, 2020 to June 22, 2020.
  • This report includes and is based around industry opinions on COVID-19's impact on clinical trials and the use of decentralized clinical trials.

Reasons to Buy

  • Understand companies' primary concerns about the COVID-19 pandemic.
  • Determine the impact of COVID-19 to date on clinical trials.
  • Assess companies' future plans to use decentralized clinical trials.
  • Track changes to clinical trial strategy and attitudes.

Table of Contents

1 Study Design

  • 1.1 Background
  • 1.2 Objectives and Design

2 Primary Business and Clinical Trial Concerns

  • 2.1 Primary Business Concerns
  • 2.2 Primary Clinical Trial Concerns
  • 2.3 Addressing Clinical Trial Disruptions

3 Movement Toward Decentralized Trials

  • 3.1 Pre-pandemic Decentralized Trials Use
  • 3.2 Post-pandemic Decentralized Trials Use
  • 3.3 Future Movement Toward Decentralized Clinical Trial Use
  • 3.4 Cost Comparison

4 Challenges Facing Decentralized Trials

  • 4.1 Biggest Challenges
  • 4.2 Biggest Changes

5 Summary

6 Appendix